# Michal Lotem

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/michal-lotem/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,909 |
| Field | Cancer Immunotherapy and Biomarkers |
| h-index | 40 |
| i10-index | 90 |
| Last Known Institution | Hebrew University of Jerusalem |
| OpenAlex ID | https://openalex.org/A5074296844 |
| ORCID iD | https://orcid.org/0000-0003-1703-8008 |
| Works | 197 |

## Researcher papers

- [Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma](https://scholariq.org/papers/ipilimumab-plus-dacarbazine-for-previously-untreated-metastatic-melanoma/)
- [Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial](https://scholariq.org/papers/adjuvant-pembrolizumab-versus-placebo-in-resected-stage-iii-melanoma-eortc-1325/)
- [Interferon-stimulated neutrophils as a predictor of immunotherapy response](https://scholariq.org/papers/interferon-stimulated-neutrophils-as-a-predictor-of-immunotherapy-response/)

## Researcher topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Immunotherapy and Immune Responses](https://scholariq.org/topics/immunotherapy-and-immune-responses/)
- [CAR-T cell therapy research](https://scholariq.org/topics/car-t-cell-therapy-research/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)
- [Immune Cell Function and Interaction](https://scholariq.org/topics/immune-cell-function-and-interaction/)

## Researcher university

- [Hebrew University of Jerusalem](https://scholariq.org/institutions/hebrew-university-of-jerusalem/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.